Amydis Diagnostics, Inc.
3210 Merryfield Row
San Diego
California
92121
United States
Tel: 858-707-5352
Website: http://www.amydis.com/
Email: info@amydis.com
About Amydis Diagnostics, Inc.
Amydis Diagnostics was founded to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease.YEAR FOUNDED:
2013
LEADERSHIP:
Founder and CEO: Stella Sarraf
Founder and CSO: Jerry Yang
CTO: Richard D’Souza
CBO: David H. Crean
CFO: Dan Albosta
11 articles about Amydis Diagnostics, Inc.
-
Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer
11/14/2023
Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers to enable imaging of disease biomarkers in the eye, announced that it has received a two-year Commercialization Readiness Pilot Program grant award of $3.4 million from The National Institutes of Health.
-
Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta
11/2/2023
Amydis Inc. announced it has launched a Phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients.
-
Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
2/21/2023
Amydis Inc. announced initiation of enrollment of patients with cerebral amyloid angiopathy, an age-associated disease in which a protein called amyloid beta builds up on the walls of the arteries in the brain increasing the risk for stroke and dementia.
-
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
10/27/2022
Amydis Inc. announced it has been awarded a third grant for $1.5M from The Michael J. Fox Foundation for Parkinson's Research.
-
Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
9/22/2022
Amydis Inc. today announced dosing of the first patients in the company’s Phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients with Parkinson’s disease.
-
Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
4/4/2022
Amydis Inc. announced the appointment of internationally recognized clinician scientist, Robert N. Weinreb M.D. as the First Chair to the Scientific Advisory Board of the Company.
-
Clinical Catch-Up: April 26-30
5/3/2021
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications. -
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies
4/26/2021
Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases in the eye, announced completion of pre-IND interaction with the U.S. Food and Drug Administration regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies.
-
NIH Awards Cerebral Amyloid Angiopathy Grant To Amydis Diagnostics, Inc.
10/9/2017
-
Amydis Diagnostics, Inc. Adds Veteran Drug Development Executive And Chief Medical Officer To Management Team
5/17/2017
-
Amydis Diagnostics, Inc. Awarded NIH Grant To Further Investigate Innovative Technology For Early Detection Of Alzheimer’s Disease
3/20/2017